Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779 | 1.00 | TDP1 (0.44) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| Hydrochloric Acid SCHEMBL28838130 | 0.98 | TDP1 (0.43) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| SCHEMBL6807352 | 0.83 | CYP2D6 (0.48) | LMNASRCCYP2D6SLC1A3SLC1A2 | |
| SCHEMBL14935796 | 0.83 | CYP2D6 (0.48) | LMNASRCCYP2D6SLC1A3SLC1A2 | |
| SCHEMBL6947260 | 0.83 | CYP2D6 (0.48) | LMNASRCCYP2D6SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL8695663 | 0.82 | CYP2D6 (0.46) | LMNASRCCYP2D6SLC1A3SLC1A2 | |
| Methane SCHEMBL4340079 | 0.82 | CYP2D6 (0.46) | LMNASRCCYP2D6SLC1A3SLC1A2 | |
| SCHEMBL22074716 | 0.79 | TDP1 (0.67) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| SCHEMBL304041 | 0.79 | TDP1 (0.47) | TDP1NR1I2PTGS1ADRA1ALMNA | |
| SCHEMBL16826249 | 0.79 | TDP1 (0.47) | TDP1NR1I2PTGS1ADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| CN-119424050-A | Degradable valve frame and heart valve | 元心科技(深圳)有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2025026273-A1 | DEGRADABLE VALVE STENT, VALVE STENT FOR PULMONARY ARTERIAL VALVE, PULMONARY ARTERIAL VALVE, AND HEART VALVE | 元心科技(深圳)有限公司 | 2025-02-06 | — | — | WO | claimed |
| EP-3655036-B1 | COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS | HOFFMAN TECH LLC (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240209409-A1 | Method for Secretory Production of Unnatural-Amino-Acid-Containing Protein | AJINOMOTO CO., INC. (JP) | 2024-06-27 | — | — | US | claimed |
| EP-4368722-A1 | METHOD FOR SECRETORY PRODUCTION OF UNNATURAL-AMINO-ACID-CONTAINING PROTEIN | AJINOMOTO CO., INC. (JP) | 2024-05-15 | — | — | EP | claimed |
| US-11931329-B2 | Compositions and methods for treating anxiety-related disorders | YAMO PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | claimed |
| US-20130274176-A1 | BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2013-10-17 | — | — | US | claimed |
| WO-2013109610-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HOFFMAN STEVEN (US) | 2013-07-25 | — | — | WO | claimed |
| US-20130184214-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-07-18 | — | — | US | claimed |
| US-8481498-B1 | Pharmaceutical compositions and methods | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-07-09 | — | — | US | claimed |
| CN-102333536-A | Ss-arrestin effectors and compositions and methods of use thereof | TREVENA INC | 2012-01-25 | — | — | CN | claimed |
| EP-2376101-A2 | ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | Trevena, Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2010-07-22 | — | — | US | claimed |
| WO-2010077339-A2 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-20090011055-A1 | Plasminogen Activator Inhibitor-1 Inhibitors And Methods Of Use Thereof To Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | US | claimed |
| WO-2008131047-A2 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | TDP1 3027/4885NR1I2 4566/4885PTGS1 2925/4885 |
| US-20090011055-A1 | Plasminogen Activator Inhibitor-1 Inhibitors And Methods Of Use Thereof To Modulate Lipid Metabolism | SERPINE1, PLAT, SERPINB1 | TDP1 2746/4885NR1I2 1060/4885PTGS1 355/4885 |
| US-20130274176-A1 | BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ARRB1, ADRB1, ADRB3 | TDP1 2200/4885NR1I2 1507/4885PTGS1 4070/4885 |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | TDP1 2200/4885NR1I2 1507/4885PTGS1 4070/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | TDP1 2893/4885NR1I2 2038/4885PTGS1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.